Leuprolide Open Label

Phase 3Small molecule

Leuprolide Open Label is one of 5 small molecule programs targeting Hormone Sensitive Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hormone Sensitive Prostate CancerActive, not recruiting

Hormone Sensitive Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Hormone Sensitive Prostate Cancer

#DrugCompanyPhaseTrials

Xtandi

Astellas

Phase 3

1 2

Opdivo

Bristol-Myers Squibb

Phase 2

1 3

Taxotere

AAvyxa

Phase 2

1 4

Androgen Deprivation Therapy

Johnson & Johnson

Phase 2

1 5

Leuprolide Open Label

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hormone Sensitive Prostate Cancer1 trial

A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT02319837·1,068 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Leuprolide Open Label. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Leuprolide Open Label compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Leuprolide Open Label. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Leuprolide Open Label

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hormone Sensitive Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News